CVRX, INC.
MINNEAPOLIS, MN

CVRX, Inc., headquartered at 9201 West Broadway Avenue in Minneapolis, MN, is a biopharmaceutical company specializing in developing and commercializing gastrointestinal therapies. Founded on September 22, 2006, CVRX has been listed under the status of a Florida Models D.O.S. Florida Company with its operational base originally set in Delaware. The corporation plays a significant role in innovative healthcare solutions aimed at improving gastrointestinal health worldwide. Over the years, it has focused on pivotal medications and treatments that target conditions such as acid-related diseases and nutrient absorption disorders. Their dedication to advancing gastroenterological therapeutics positions them prominently within the biopharmaceutical sector. The company maintains transparency with its investors and stakeholders through regular disclosures and has a history of regulatory compliance marked by key events, including its reinstatement on October 16, 2007. CVRX is overseen by distinguished leaders like Paul Verrastro as Chief Executive Officer and supported by influential directors such as Ali Behbahani and Kevin Hykes. The company upholds strategic oversight facilitated through seasoned management with varied expertise and substantial backgrounds in healthcare investment and operational leadership across pharmaceutical sectors. Staying connected with its community, CVRX provides updated information via its corporate website (www.cvrx.com) and continues to advance therapeutic developments backed by financial acumen from entities like New Enterprise Associates. The future direction of CVRx reflects a commitment to innovation that not only prioritizes patient care but also seeks sustainable growth in the competitive field of biopharmaceuticals.